Related Experiment Video
Updated: May 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The causal relationship between 179 lipid species and urolithiasis: a bidirectional and multivariable Mendelian
Xidong Wang1, Yingying Yang1, Gang Wu1
1Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, NO. 20 East Yuhuangding Road, Yantai, Shandong, China.
Background:
Previous research has suggested a potential link between urolithiasis and lipid species levels. A Mendelian randomization (MR) study was conducted to investigate whether a causal relationship exists between genetic susceptibility to plasma lipids and the risk of urolithiasis.
Methods:
Data on lipid species were collected from genome-wide association (GWAS) analyses of plasma lipidomes. For the initial analysis, GWAS data on urolithiasis were extracted using the GWAS ID ebi-a-GCST90018935. The inverse variance weighted (IVW) approach was utilized as the main method for MR analysis. Multivariable MR, multiple supplementary analyses, and comprehensive sensitivity analyses were also conducted. Additional independent datasets were utilized for replication analysis and meta-analysis.
Results:
Findings from the IVW method, repeated analyses, and meta-analysis revealed six significant causal effects of lipid species on urolithiasis. The specific lipid species identified were: phosphatidylcholine (PC; 16:1_20:4) levels [OR: 0.92; 95%CI: 0.87, 0.96; P = 6 × 10- 4], PC (16:0_20:4) levels [OR: 0.94; 95%CI: 0.90, 0.98; P = 0.0017], phosphatidylethanolamine (PE; 18:2_0:0) levels [OR: 1.10; 95%CI: 1.04, 1.15; P = 4 × 10- 4], PE (16:0_20:4) levels [OR: 1.05; 95%CI: 1.01, 1.09; P = 0.0028], PE (18:1_18:1) levels [OR: 1.06; 95%CI: 1.01, 1.11; P = 0.0136], and sterol ester (SE; 27:1/20:4) levels [OR: 0.93; 95%CI: 0.89, 0.96; P = 1.5 × 10- 4].
Conclusion:
The MR study proposes a potential causal link between six plasma lipids and urolithiasis. Particularly, SEs (27:1/20:4), PC (16:0_20:4), and PC (16:1_20:4) may serve as potential inhibitors of calcium-containing urolithiasis growth. The integration of genomics and lipidomics in MR analysis holds promise for early screening, prevention, and treatment of urinary tract stones.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Urinary Tract Calculi I: Introduction
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi VI: Surgical Management

